Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Linde
LIN
|
+$554M |
| 2 |
Apple
AAPL
|
+$513M |
| 3 |
Illumina
ILMN
|
+$360M |
| 4 |
argenx
ARGX
|
+$304M |
| 5 |
CTLT
CATALENT, INC.
CTLT
|
+$235M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$482M |
| 2 |
Sherwin-Williams
SHW
|
+$314M |
| 3 |
AbbVie
ABBV
|
+$310M |
| 4 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$244M |
| 5 |
Atlassian
TEAM
|
+$233M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.85% |
| 2 | Healthcare | 19.69% |
| 3 | Industrials | 10.47% |
| 4 | Financials | 10.02% |
| 5 | Consumer Discretionary | 9.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
776
Kimberly-Clark
KMB
$36.1B
| $7.31M | ﹤0.01% |
54,467
-34,656
| -39% | -$4.5M |
|
777
Stem
STEM
$52.8M
| $7.28M | ﹤0.01% |
64,179
+734
| +1% | +$124K |
|
778
Olema Pharmaceuticals
OLMA
$913M
| $7.28M | ﹤0.01% |
2,085,179
-972,127
| -32% | -$3.97M |
|
779
STAAR Surgical
STAA
$1.24B
| $7.28M | ﹤0.01% |
113,774
+61,999
| +120% | +$4.05M |
|
780
Scotiabank
BNS
$108B
| $7.25M | ﹤0.01% |
144,110
| – | – |
|
|
BLU
781
DELISTED
BELLUS Health Inc.
BLU
| $7.17M | ﹤0.01% |
994,579
-9,282
| -0.9% | -$72K |
|
782
Super Micro Computer
SMCI
$20.4B
| $7.13M | ﹤0.01% |
668,790
+67,340
| +11% | +$608K |
|
783
Fox Class A
FOXA
$26.1B
| $7.1M | ﹤0.01% |
208,540
+177,803
| +578% | +$6.01M |
|
784
Dominion Energy
D
$59.9B
| $7.05M | ﹤0.01% |
126,090
-49,712
| -28% | -$2.91M |
|
785
Xometry
XMTR
$5.24B
| $7.03M | ﹤0.01% |
469,641
+1,179
| +0.3% | +$31K |
|
786
Ventas
VTR
$44.6B
| $6.99M | ﹤0.01% |
161,218
+81,920
| +103% | +$3.95M |
|
787
Wheaton Precious Metals
WPM
$61B
| $6.96M | ﹤0.01% |
144,654
-17,699
| -11% | -$774K |
|
788
Allstate
ALL
$66.3B
| $6.92M | ﹤0.01% |
62,473
+28,662
| +85% | +$3.62M |
|
789
Deutsche Bank
DB
$71.8B
| $6.88M | ﹤0.01% |
675,710
-12,547
| -2% | -$150K |
|
790
Grab
GRAB
$15.3B
| $6.85M | ﹤0.01% |
2,276,243
-1,760,170
| -44% | -$5.85M |
|
791
Takeda Pharmaceutical
TAK
$55.8B
| $6.79M | ﹤0.01% |
411,818
-15,842
| -4% | -$252K |
|
792
Doximity
DOCS
$4.65B
| $6.76M | ﹤0.01% |
208,644
+60,917
| +41% | +$2.02M |
|
793
Crinetics Pharmaceuticals
CRNX
$8.95B
| $6.69M | ﹤0.01% |
416,252
+9,988
| +2% | +$185K |
|
794
Truist Financial
TFC
$63.9B
| $6.67M | ﹤0.01% |
195,732
-109,158
| -36% | -$4.77M |
|
795
Shopify
SHOP
$196B
| $6.67M | ﹤0.01% |
139,250
-400
| -0.3% | -$17.6K |
|
796
Medpace
MEDP
$16.9B
| $6.64M | ﹤0.01% |
35,327
-31,013
| -47% | -$6.41M |
|
797
Exelon
EXC
$46.2B
| $6.58M | ﹤0.01% |
157,075
-115,861
| -42% | -$4.83M |
|
798
Viking Therapeutics
VKTX
$3.94B
| $6.52M | ﹤0.01% |
+391,136
| New | +$4.04M |
|
799
Idexx Laboratories
IDXX
$46.2B
| $6.51M | ﹤0.01% |
13,015
+2,547
| +24% | +$1.22M |
|
800
Leggett & Platt
LEG
$1.3B
| $6.49M | ﹤0.01% |
203,506
+87,885
| +76% | +$2.96M |
|
Similar funds
Janus Henderson Group's Q1 2023 Portfolio in Review
As of Q1 2023, Janus Henderson Group held 2,845 positions worth $152B, up 8.3% from $140B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Janus Henderson Group's Q1 2023 filing shows 389 new, 1,670 increased, 578 reduced and 160 closed positions. Its largest new stake was GE HealthCare: 882,749 shares worth $72.4M. The largest sale was Meta Platforms (Facebook), an estimated $482M.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 28% a quarter earlier, followed by Healthcare and Industrials.
- Janus Henderson Group's largest Q1 2023 buy was GE HealthCare: 882,749 shares worth $72.4M.
- Janus Henderson Group added most to Linde in Q1 2023, an estimated $554M increase.
- Janus Henderson Group's biggest Q1 2023 reduction was Meta Platforms (Facebook), cutting an estimated $482M.
- Janus Henderson Group fully exited Myovant Sciences Ltd. in Q1 2023, selling an estimated $31.7M.
- Janus Henderson Group's ten largest holdings make up 24% of its $152B portfolio in Q1 2023.
- Janus Henderson Group opened 389 new positions and closed 160 in Q1 2023.
- Janus Henderson Group's portfolio value rose 8.3% quarter-over-quarter to $152B.
Based on Janus Henderson Group's 13F filing for Q1 2023, filed 15 May 2023.